Demodex Blepharitis in Scleral Lens Wearers
Starting soon · Phase 4
Conditions studied: Demodex Blepharitis
In brief
The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance. The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.
Key facts
- Study ID
- NCT07561450
- Run by
- Boston Sight
- People needed
- 5
- Starts
- 2026-04-27
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2026-05-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Is currently participating in any other type of eye-related clinical research study
- Is pregnant or nursing as reported by the subject.
- Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
- Has had previous ocular surgery within the past 12 weeks or has planned ocular surgery during the study period.
- Has initiated any new blepharitis or ocular surface treatment within the last 12 weeks
- The subject is only wearing a PROSE device in one eye.
- The participant is monocular
- The participant carries a diagnosis of glaucoma or ocular hypertension or glaucoma suspect AND is currently using glaucoma medications
- Allergy to sodium fluorescein
- Allergy to XDEMVY (lotilaner ophthalmic solution) 0.25%
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.